CoolSculpting, owned by global pharmaceutical company Allergan, has received FDA clearance to treat the submandibular area.
Manufacturer of aesthetic laser solutions and equipment, Alma Lasers, has launched a new treatment protocol which amalgamates two applicators, aiming to promote longer-lasting skin tightening and fat reduction in areas that are more challenging to reach.
UK laser manufacturer, Laser Lipo has introduced a new treatment that aims to provide a non-invasive, pain-free neck, double chin and jowl reduction in just 12 minutes.
Juvea Medical on Harley Street has become the first clinic in the UK to offer the body contouring laser treatment SculpSure for the submental area.
Body contouring laser device SculpSure has received CE certification for treating the submental area.
A survey has suggested that 47% of adults are bothered by the appearance of the area under their chin.
Global pharmaceutical company Allergan has received a ‘positive opinion’ from the Swedish Medical Products Agency (MPA) for BELKYRA.
The Food and Drugs Administration (FDA) has approved Kybella as a treatment for moderate to severe submental fat.
Research presented at the 2014 annual meeting of the American Society for Aesthetic Plastic Surgery (ASAPS), previously presented at the American Society for Dermatologic Surgery, shows that a new injectable treatment could be effective as a non-invasive treatment for submental fat reduction.
The US phase 3 trials of new fat dissolving injectable ATX-101 developed by US biopharmaceutical company Kythera have shown statistically significant reductions in submental fat (double chin). The results of the trials were presented by Dr Jean Curruthers at the annual meeting of the American Society for Dermatologic Surgery. Two studies of more than 1,000 patients with moderate to severe submental fat were conducted with patients having up to six treatments at roughly one month intervals. Approximately half had all six injections, with 70.3% and 66.9% showing a clinically meaningful improvement in the first and second trials respectively.